Quarterly ResultMay 4, 2026, 04:14 PM
Inspire Medical Q1 Net Loss $(11.3)M; Revenue $204.6M
AI Summary
Inspire Medical Systems reported a net loss of $(11.3) million for Q1 2026, a significant decline from a $3.0 million net income in Q1 2025, despite a slight revenue increase to $204.6 million. The company is facing multiple securities class action lawsuits and derivative lawsuits related to the Inspire V neurostimulator launch, as well as a Department of Justice civil investigative demand and a False Claims Act qui tam lawsuit. Inspire also filed a patent infringement lawsuit against Nyxoah SA.
Key Highlights
- Net loss of $(11.3) million in Q1 2026, compared to net earnings of $3.0 million in Q1 2025.
- Revenue increased to $204.6 million in Q1 2026 from $201.3 million in Q1 2025.
- Basic loss per share was $(0.39) in Q1 2026, down from $0.10 earnings per share in Q1 2025.
- Operating loss improved to $(1.1) million in Q1 2026 from $(1.5) million in Q1 2025.
- Income tax expense surged to $13.7 million in Q1 2026 from $1.2 million in Q1 2025.
- Net cash provided by operating activities was $12.8 million in Q1 2026, reversing a $(6.7) million use in Q1 2025.
- Facing multiple securities class action and derivative lawsuits related to Inspire V launch.
- Subject to a DOJ civil investigative demand and a False Claims Act qui tam lawsuit.